BMO Capital Markets upgraded its rating on shares of Halozyme Therapeutics Inc. (HALO) Monday to "Outperform" from "Market Perform."
Halozyme Therapeutics gapped up sharply Monday and climbed throughout the first 2 hours of trade. The stock finished up by 1.13 at $8.34 on above average volume and leaped to nearly a 4-month high.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org